287 related articles for article (PubMed ID: 22357997)
1. Is gadoxetate disodium-enhanced MRI useful for detecting local recurrence of hepatocellular carcinoma after radiofrequency ablation therapy?
Watanabe H; Kanematsu M; Goshima S; Yoshida M; Kawada H; Kondo H; Moriyama N
AJR Am J Roentgenol; 2012 Mar; 198(3):589-95. PubMed ID: 22357997
[TBL] [Abstract][Full Text] [Related]
2. Characteristics and distinguishing features of hepatocellular adenoma and focal nodular hyperplasia on gadoxetate disodium-enhanced MRI.
Purysko AS; Remer EM; Coppa CP; Obuchowski NA; Schneider E; Veniero JC
AJR Am J Roentgenol; 2012 Jan; 198(1):115-23. PubMed ID: 22194486
[TBL] [Abstract][Full Text] [Related]
3. Biologic factors affecting HCC conspicuity in hepatobiliary phase imaging with liver-specific contrast agents.
Kim JY; Lee SS; Byun JH; Kim SY; Park SH; Shin YM; Lee MG
AJR Am J Roentgenol; 2013 Aug; 201(2):322-31. PubMed ID: 23883212
[TBL] [Abstract][Full Text] [Related]
4. MRI assessment of biliary ductal obstruction: is there added value of T1-weighted gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid-enhanced MR cholangiography?
Reiner CS; Merkle EM; Bashir MR; Walle NL; Nazeer HK; Gupta RT
AJR Am J Roentgenol; 2013 Jul; 201(1):W49-56. PubMed ID: 23789696
[TBL] [Abstract][Full Text] [Related]
5. Gadoxetate disodium-enhanced MR imaging: differentiation between early-enhancing non-tumorous lesions and hypervascular hepatocellular carcinomas.
Goshima S; Kanematsu M; Watanabe H; Kondo H; Mizuno N; Kawada H; Shiratori Y; Onozuka M; Moriyama N; Bae KT
Eur J Radiol; 2011 Aug; 79(2):e108-12. PubMed ID: 21592707
[TBL] [Abstract][Full Text] [Related]
6. Added value of gadoxetic acid-enhanced hepatobiliary phase MR imaging in the diagnosis of hepatocellular carcinoma.
Ahn SS; Kim MJ; Lim JS; Hong HS; Chung YE; Choi JY
Radiology; 2010 May; 255(2):459-66. PubMed ID: 20413759
[TBL] [Abstract][Full Text] [Related]
7. Diagnostic performance of gadoxetic acid-enhanced liver MR imaging in the detection of HCCs and allocation of transplant recipients on the basis of the Milan criteria and UNOS guidelines: correlation with histopathologic findings.
Lee DH; Lee JM; Baek JH; Shin CI; Han JK; Choi BI
Radiology; 2015 Jan; 274(1):149-60. PubMed ID: 25203131
[TBL] [Abstract][Full Text] [Related]
8. Detection of liver malignancy with gadoxetic acid-enhanced MRI: is addition of diffusion-weighted MRI beneficial?
Kim YK; Kim CS; Han YM; Lee YH
Clin Radiol; 2011 Jun; 66(6):489-96. PubMed ID: 21367403
[TBL] [Abstract][Full Text] [Related]
9. Added value of breathhold diffusion-weighted MRI in detection of small hepatocellular carcinoma lesions compared with dynamic contrast-enhanced MRI alone using receiver operating characteristic curve analysis.
Xu PJ; Yan FH; Wang JH; Lin J; Ji Y
J Magn Reson Imaging; 2009 Feb; 29(2):341-9. PubMed ID: 19161186
[TBL] [Abstract][Full Text] [Related]
10. Detection of hepatocellular carcinoma in gadoxetic acid-enhanced MRI and diffusion-weighted MRI with respect to the severity of liver cirrhosis.
Kim AY; Kim YK; Lee MW; Park MJ; Hwang J; Lee MH; Lee JW
Acta Radiol; 2012 Oct; 53(8):830-8. PubMed ID: 22847903
[TBL] [Abstract][Full Text] [Related]
11. Detection of liver metastases using gadoxetic-enhanced dynamic and 10- and 20-minute delayed phase MR imaging.
Jeong HT; Kim MJ; Park MS; Choi JY; Choi JS; Kim KS; Choi GH; Shin SJ
J Magn Reson Imaging; 2012 Mar; 35(3):635-43. PubMed ID: 22095933
[TBL] [Abstract][Full Text] [Related]
12. Pseudolesion of the liver on gadoxetate disodium-enhanced MR images obtained after transarterial chemoembolization for hepatocellular carcinoma: clinicoradiologic correlation.
Shinagawa Y; Sakamoto K; Fujimitsu R; Shimakura M; Kora S; Takano K; Yoshimitsu K
AJR Am J Roentgenol; 2012 Nov; 199(5):1010-7. PubMed ID: 23096173
[TBL] [Abstract][Full Text] [Related]
13. Gadoxetate disodium-enhanced magnetic resonance imaging versus contrast-enhanced 18F-fluorodeoxyglucose positron emission tomography/computed tomography for the detection of colorectal liver metastases.
Seo HJ; Kim MJ; Lee JD; Chung WS; Kim YE
Invest Radiol; 2011 Sep; 46(9):548-55. PubMed ID: 21577131
[TBL] [Abstract][Full Text] [Related]
14. MRI for detection of hepatocellular carcinoma: comparison of mangafodipir trisodium and gadopentetate dimeglumine contrast agents.
Youk JH; Lee JM; Kim CS
AJR Am J Roentgenol; 2004 Oct; 183(4):1049-54. PubMed ID: 15385303
[TBL] [Abstract][Full Text] [Related]
15. Distinguishing hypervascular pseudolesions of the liver from hypervascular hepatocellular carcinomas with gadoxetic acid-enhanced MR imaging.
Motosugi U; Ichikawa T; Sou H; Sano K; Tominaga L; Muhi A; Araki T
Radiology; 2010 Jul; 256(1):151-8. PubMed ID: 20574092
[TBL] [Abstract][Full Text] [Related]
16. Gadoxetate disodium-enhanced hepatobiliary phase MRI of hepatocellular carcinoma: correlation with histological characteristics.
Choi JY; Kim MJ; Park YN; Lee JM; Yoo SK; Rha SY; Seok JY
AJR Am J Roentgenol; 2011 Aug; 197(2):399-405. PubMed ID: 21785086
[TBL] [Abstract][Full Text] [Related]
17. Prediction of microvascular invasion of hepatocellular carcinoma: usefulness of peritumoral hypointensity seen on gadoxetate disodium-enhanced hepatobiliary phase images.
Kim KA; Kim MJ; Jeon HM; Kim KS; Choi JS; Ahn SH; Cha SJ; Chung YE
J Magn Reson Imaging; 2012 Mar; 35(3):629-34. PubMed ID: 22069244
[TBL] [Abstract][Full Text] [Related]
18. Small (≤1-cm) hepatocellular carcinoma: diagnostic performance and imaging features at gadoxetic acid-enhanced MR imaging.
Yu MH; Kim JH; Yoon JH; Kim HC; Chung JW; Han JK; Choi BI
Radiology; 2014 Jun; 271(3):748-60. PubMed ID: 24588677
[TBL] [Abstract][Full Text] [Related]
19. Can the patient with cirrhosis be imaged for hepatocellular carcinoma without gadolinium?: Comparison of combined T2-weighted, T2*-weighted, and diffusion-weighted MRI with gadolinium-enhanced MRI using liver explantation standard.
Hardie AD; Kizziah MK; Rissing MS
J Comput Assist Tomogr; 2011; 35(6):711-5. PubMed ID: 22082541
[TBL] [Abstract][Full Text] [Related]
20. Comparison of gadoxetic acid-enhanced MR imaging versus four-phase multi-detector row computed tomography in assessing tumor regression after radiofrequency ablation in subjects with hepatocellular carcinomas.
Yoon JH; Lee EJ; Cha SS; Han SS; Choi SJ; Juhn JR; Kim MH; Lee YJ; Park SJ
J Vasc Interv Radiol; 2010 Mar; 21(3):348-56. PubMed ID: 20116285
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
